Please wait while the formulary information is being retrieved.
CUVRIOR (trientine tetrahydrochloride)
- excessive copper deposits in the liver and brain
300 mg tablet
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Iron deficiency anemia
CUVRIOR (trientine tetrahydrochloride)
- excessive copper deposits in the liver and brain
- Anemia
- None
More Frequent
Severe
Less Severe
- Systemic lupus erythematosus
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acquired dystonia
- Allergic dermatitis
- Skin rash
- Urticaria
Less Severe
- Muscle spasm
- Muscle weakness
- Pruritus of skin
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Trientine Tetrahydrochloride
Safety and efficacy not established in age < 5 years.
Monitor for copper and iron deficiency.
- 1 Day – 5 Years
- Safety and efficacy not established in age < 5 years.
- Monitor for copper and iron deficiency.
- 5 Years – 18 Years
- Safety and efficacy not established in age < 5 years.
- Monitor for copper and iron deficiency.
Trientine
- Severity Level:
2
- Additional Notes: Limited data do not suggest dev tox; consider maternal benefit vs neonatal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Trientine
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Wilson's disease | |
| E83.01 | Wilson's disease |
| 0-9 | A-Z |
|---|---|
| E83.01 | Wilson's disease |
Formulary Reference Tool